Mumbai: Torrent Pharmaceuticals Ltd has entered into an agreement with Dr Reddy's Laboratories Ltd (DRL) for exclusive commercialisation of two of the company's cardiovascular drug brands - Listril (Lisinopril) and Listril Plus (Lisinopril HCTZ) - in Russia.

Both Listril and Listril Plus are used in the treatment of high blood pressure. The agreement offers the potential for immediate commercialisation of the two brands as they have already been registered in Russia.

While Torrent will own the registration and trademarks of both the brands, DRL will get exclusive marketing rights to them. The deal will put both the companies in an advantageous position in the cardiovascular segment in the Russian market.

This is the second such agreement that the Torrent has signed with DRL for the Russian market. The first was for licensing and supplying the formulation of one of its blockbuster drug "Domstal O" (Domperidone + Omeprazole in the gastro-intestinal segment in July 2004.

The company had licensed the dossier and marketing authorisation for the formulation to DRL, which it will soon launch under the brand name Omez D in Ukraine and Kazakhstan, followed by Russia and Belarus.